A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Vice President - Early Pipeline Delivery

Clinical Research OperationsConfirmed live in the last 24 hours
Full-timeUnited StatesIn-person

About the Job

Requirements

  • A Master of Science, Master of Business Administration, PhD, or equivalent in a relevant discipline is strongly preferred.
  • At least 20 years of industry experience focused on Clinical Operations, including significant experience leading early-stage study management within a biopharmaceutical company and direct accountability for Phase 1/2 program delivery.
  • A track record of building or scaling a team or operating function, ideally including establishing new organizational capabilities in a growth environment.
  • Experience with first-in-human and healthy-volunteer study designs; exposure to novel or emerging geographies is a plus.
  • Strong operational and analytical rigor, including comfort using data and benchmarking to diagnose bottlenecks and drive continuous improvement.
  • Executive presence and communication skills sufficient to influence senior R&D leadership and partner functions without direct authority.
  • Familiarity with applying AI-enabled tools to clinical feasibility and enrollment forecasting.

Responsibilities

  • Lead onboarding and build-out of the new Early Pipeline Delivery team, expanding its scope to additional studies as the team scales and development candidates are endorsed to move into the clinic.
  • Recruit, develop, and manage a team of study leads who carry operational accountability for early-stage studies.
  • Serve as the senior point of accountability for early-phase studies, providing hands-on leadership on priority programs while building organizational depth.
  • Design and evolve the operating model, scaling toward a fully dedicated early pipeline study management function.
  • Develop and institutionalize a playbook covering healthy-volunteer and patient models, country strategy, protocol operationalization, and vendor selection, ensuring learnings transfer across programs.
  • Integrate adaptive execution practices across Pipeline Delivery and partnering functions, and apply AI-enabled tools for feasibility and enrollment forecasting to accelerate proof-of-concept timelines.
  • Establish standardized ways of working and consistent performance oversight across early development studies, replacing a reactive, program-by-program approach with proactive risk anticipation.
  • Partner with Global Trial Strategy & Operations, Research & Early Development, and Technical Operations & Quality to manage the critical path from development candidate nomination through clinical trial application and into proof of concept.
  • Provide input on portfolio prioritization and resourcing, ensuring Early Pipeline Delivery leadership maintains sufficient influence and connectivity across dedicated and transitioning studies.
  • Support delivery of complex, novel study types, including first-in-human, healthy-volunteer, and novel-country studies, and emerging therapeutic areas such as ophthalmology and neuromuscular disease.
  • Represent Early Pipeline Delivery to senior R&D and Pipeline Delivery leadership, reporting on progress, risks, and resourcing needs as the function scales.

Desired Qualifications

  • Exposure to novel or emerging geographies.
  • A builder's mindset, energized by ambiguity and the opportunity to shape a new function rather than inherit an established one.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs